Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEffect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
American Journal of Medicine, 09/29/09
Abourbih S et al. – In addition to improving lipid profiles, fibrates are associated with an important decrease in nonfatal myocardial infarction, but do not substantially affect all–cause mortality. Potential applications include treatment for patients with statin resistance or isolated hypertriglyceridemia, or as an adjunct to other lipid–lowering therapies.
Methods- The authors systematically searched the literature to identify randomized, double–blind, placebo–controlled trials examining the effect of fibrates on lipid profiles or cardiovascular outcomes
- The authors estimated the effect of fibrates on the incidence of nonfatal myocardial infarction and all–cause mortality using random effects models.
- Compared with placebo, fibrates were associated with greater reductions in total cholesterol (range: ?101.3 mg/dL to ?5.0 mg/dL) and triglycerides (range: ?321.3 mg/dL to ?20.8 mg/dL), and a greater increase in high–density lipoprotein (range: +1.1 mg/dL to +17.9 mg/dL) in all trials.
- Fibrates tended to be associated with a greater reduction in low–density lipoprotein (range: ?76.3 mg/dL to +38.7 mg/dL) than placebo, although these results were not consistent across all trials.
- Fibrates were more efficacious than placebo at preventing nonfatal myocardial infarction, but not all–cause mortality.
Related Articles
Dietary cholesterol and coronary artery disease: A systematic review
Current Atherosclerosis Reports, 11/11/09
Relevance Score: 93%
Cardiovascular disease-related genes and regulation by diet
Current Atherosclerosis Reports, 11/17/09
Relevance Score: 92%
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA
Expert Review of Cardiovascular Therapy, 11/16/09
Relevance Score: 89%
Acute, food-induced moderate elevation of plasma uric acid protects against hyperoxia-induced oxidative stress and increase in arterial stiffness in healthy humans
Atherosclerosis, 11/17/09
Relevance Score: 88%
Comparison of Bleeding Complications With Omega-3 Fatty Acids + Aspirin + Clopidogrel—Versus—Aspirin + Clopidogrel in Patients With Cardiovascular Disease
The American Journal of Cardiology, 10/13/09
Relevance Score: 88%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/29/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Beta-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Annals of Pharmacotherapy, 11/25/09
Sponsor
Article Search
Sponsor